Skip to main content
Year archive

Camurus — 2018 filings

All 41 regulatory filings released by Camurus (CAMX) in 2018, sourced directly from the official regulator.

41 Filings
2018 Period
2018 filings (41)
Filing Released Lang
US FDA issues a tentative approval of Brixadi™ (buprenorphine) extended-release injection for treatment of opioid use disorder
Regulatory Filings
2018-12-23 English
FDA utfärdar tentativt godkännande för Brixadi™ (CAM2038) för behandling av opioidberoende
Regulatory Filings
2018-12-23 Swedish
Major Shareholding Notification 2018
Major Shareholding Notification
2018-12-04 English
Buvidal® Weekly and Buvidal® Monthly (CAM2038) approved in Australia as the first long-acting treatment of opioid dependence
Regulatory Filings
2018-11-28 English
Buvidal® godkänd som första långtidsverkande behandling av opioidberoende i Australien
Regulatory Filings
2018-11-28 Swedish
Camurus receives EU approval for weekly and monthly Buvidal® (CAM2038) for opioid dependence
Regulatory Filings
2018-11-22 English
Camurus får EU-godkännande för Buvidal® (CAM2038) vecko- och månadsdepåer mot opioidberoende
Regulatory Filings
2018-11-22 Swedish
Interim / Quarterly Report 2018
Interim / Quarterly Report 9M 2018
2018-10-25 Swedish
Interim / Quarterly Report 2018
Interim / Quarterly Report Q3 2018
2018-10-25 English
Valberedning utsedd inför Camurus årsstämma 2019
AGM Information
2018-10-16 Swedish
Camurus’ Nomination Committee appointed for the Annual General Meeting 2019
Board/Management Information
2018-10-16 English
CHMP rekommenderar godkännande av Buvidal® (CAM2038) för behandling av opioidberoende
Regulatory Filings
2018-09-21 Swedish
CHMP recommends approval of Buvidal® (CAM2038) for the treatment of opioid dependence
Regulatory Filings
2018-09-21 English
Camurus meddelar positiva fas 3-resultat för CAM2038 i patienter med kronisk smärta
Regulatory Filings
2018-09-18 Swedish
Camurus announces positive topline Phase 3 results for CAM2038 in opioid experienced patients with chronic low-back pain
Regulatory Filings
2018-09-18 English
Interim / Quarterly Report 2018
Interim / Quarterly Report H1 2018
2018-07-17 Swedish
Interim / Quarterly Report 2018
Interim / Quarterly Report Q2 2018
2018-07-17 English
Camurus meddelar att FDA aviserat PDUFA-datum för CAM2038
Regulatory Filings
2018-07-16 Swedish
Camurus announces PDUFA date for CAM2038 for the treatment of opioid use disorder
Earnings Release Q4 2018
2018-07-16 English
Ändring av antalet aktier och röster i Camurus AB
Declaration of Voting Results & Voting Rights Announcements
2018-06-29 Swedish
Change in the number of shares and votes in Camurus AB
Declaration of Voting Results & Voting Rights Announcements
2018-06-29 English
Camurus has completed a directed share issue of 1.1 million shares, raising proceeds of approximately SEK 102 million
Share Issue/Capital Change
2018-06-29 English
Camurus har genomfört en riktad nyemission om 1,1 miljoner aktier och tillförs härigenom cirka 102 miljoner kronor
Share Issue/Capital Change
2018-06-29 Swedish
Camurus intends to launch a directed share issue of approx. MSEK 100
Share Issue/Capital Change
2018-06-28 English
Camurus avser genomföra riktad nyemission om ca 100 MSEK
Share Issue/Capital Change
2018-06-28 Swedish
Camurus meddelar att en uppdaterad registreringsansökan för långtidsverkande buprenorfin, CAM2038, lämnats in till FDA
Regulatory Filings
2018-05-28 Swedish
Camurus announces NDA resubmission of weekly and monthly buprenorphine depots to FDA
Regulatory Filings
2018-05-28 English
Resolutions at the annual general meeting 2018 in Camurus
AGM Information
2018-05-03 English
Beslut vid Camurus årsstämma 2018
AGM Information
2018-05-03 Swedish
Interim / Quarterly Report 2018
Interim / Quarterly Report Q1 2018
2018-05-03 Swedish
Interim / Quarterly Report 2018
Interim / Quarterly Report Q1 2018
2018-05-03 English
Camurus återtar de globala utvecklings- och kommersialiseringsrättigheterna till CAM2029 och andra relaterade produktkandidater
Regulatory Filings
2018-05-03 Swedish
Camurus regains worldwide development and commercialization rights to CAM2029 and related product candidates
Regulatory Filings
2018-05-03 English
Kallelse till årsstämma 2018 i Camurus AB (publ)
AGM Information
2018-03-23 Swedish
Notice of annual general meeting 2018 in Camurus AB (publ)
AGM Information
2018-03-23 English
Annual Report 2017
Annual Report FY 2017
2018-03-22 Swedish
Annual Report 2017
Annual Report FY 2017
2018-03-22 English
Earnings Release 2017
Earnings Release Q4 2017
2018-02-15 Swedish
Annual Report 2017
Annual Report FY 2017
2018-02-15 English
FDA utfärdar Complete Response Letter för CAM2038 mot opioidberoende
Legal Proceedings Report
2018-01-21 Swedish
FDA issues complete response letter for CAM2038 for opioid use disorder
Regulatory Filings
2018-01-21 English